Abstract. Tyr-3-Octreotide is a synthetic derivative of somatostatin and a somatostatin-receptor analogue. The iodine-123-1abelled compound localizes somatostatin-receptor-positive tumours. In this paper two patients are reported in whom somatostatin receptors were demonstrated in vitro. In a 60-year-old female with an islet cell carcinoma of the pancreas, multiple liver metastases and previously unrecognized bone metastases in the right acetabulum could be diagnosed as the reason for a persistent hypoglycaemia. In a 60-year-old male an islet cell carcinoma of the pancreas was localized with lz3I-Tyr-3-octreotide. The somatostatin receptors were demonstrated in vitro and the turnout was successfully treated with somatostatin. These studies demonstrate that lz3I-Tyr-3-octreotide offers the possibility of localizing somatostatin-receptor-positive tumours and their metastases. Moreover the method makes it possible to determine the receptor status of a tumour in vivo.
Introduction
Iodine 123 tyr-3-octreotide 201-995, a synthetic derivative of somatostatin, is a somatostatin receptor analogue (Bakker et al. 1990 ) which has been introduced for the localization of somatostatin receptor-positive tumours (Krenning et al. 1989; Lamberts et al. 1990a, b, c) . A parallel between the evidence of somatostatin receptors on tumours and in vivo and in vitro effects of octreotide on hormonal release from these tumours indicates that a positive scan predicts a good suppressive effect of octreotide on hormonal hypersecretion by these endocrine tumours. This is one of the possible future indications for an iodine 123 tyr-3-octreotide scan. Another indication is based on the fact that, with the exception of insulinomas, most endocrine pancreatic tumours are malignant and have already metastasized at the time of diagnosis (Bloom and Polak 1980; Stefani et al. 1974 ), so surgery is considered to be the primary treatment. For this reason, a specific and sensitive method for the localization of all tumour manifestations is required.
This case report confirms the positive result of previous papers dealing with iodine 123 tyr-3-octreotide (Krenning et al. 1989; Lamberts et al. 1990a, b, c) . Nontumour related uptake is also described.
Materials and patients
Radiopharmaceuticals. The radiolabelling of tyr-3-octreotide was performed according to a previously published method (Bakker et al. 1990 ). Tyr-3-octreotide was obtained from Sandoz (Basel, Switzerland) . The radioiodination of the tracer was performed with ~23I from Medgenix, Belgium. The radioactivity concentration and specific activities amounted to 3.7 GBq/ml. Normal patient activity was 185 MBq iodine 123 tyr-3-octreotide. There were no side effects recorded. All patients gave their written informed consent for this examination.
Data acquisition. Gamma-camera images were performed as planar (128 x 128 matrix) and SPET images (64 x 64 matrix) with a Siemens Rota gamma-camera fitted with a low-energy, high-resolution collimator. Data were collected with a Siemens Microdelta computer. The image time was routinely 5-45 min post injection (p.i.) and 2-3 h p.i. The relevant images were performed during the first 30 rain, before the beginning of the intestinal excretion of the 12aI-labelled metabolites of tyr-3-octreotide. The SPET image of the liver was performed 2 h p.i. after significant clearance of the iodine by the liver.
In vitro determination of somatostatin receptors. Somatostatin receptors were measured by autoradiography on cryostat sections of the turnout tissues as described previously in detail for various endocrine tumours (Reubi et al. 1987 .
Case reports
Patient 1. A 60-year-old man who suffered from a weight loss of 10 kg and heavy diarrhoea during the past 2 months was admit- Fig. 1 . A 60-year-old man with somatostatin receptor-positive, non-resectable pancreatic islet carcinoma, which is specifically shown with iodine 123 tyr-3-octreotide between the activity of both kidneys in a planar abdominal scan ted to our hospital (April 1984) . Ultrasound, computed X-ray tomography and magnetic resonance imaging localised a pancreatic mass of 9 x 6 cm diameter with compression of the vena cava and aorta without any signs of infiltration but with occlusion of the vena lienalis and the vena mesenterica superior. The tumour of the pancreas produced no clinically detectable product and was judged to be inactive.
During explorative surgery the tumour proved not to be resectable (May 1984) . Biopsy specimen of the tumour revealed an islet cell carcinoma. At that time the autoradiography of somatostatin receptors was not yet possible, and Sandostatin was not available. The patient underwent 21 courses of fluorouracil and streptozocin treatment over the subsequent 3 years. The tumour size did not change, but the symptoms, especially weakness and faintness, increased. At this time (Nov. 1987) an ultrasound-guided biopsy of the pancreatic turnout was examined with autoradiography, which demonstrated a significant number of somatostatin receptors expressed on the turnout tissue. Following this diagnosis treatment with 3 x 500 jig of Sandostatin given subcutaneously was started. From this time on, the patient recovered quickly, and the tumour size decreased slightly. In Aug. 1990 an iodine 123 tyr-3-octreotide scan was performed after a 3-day interruption of the Sandostatin treatment. The scan (Fig. 1) demonstrated a large tumour mass between both kidneys and under the liver with significant tracer uptake. Other manifestations of the tumour could not be detected.
Patient 2. A 60-year-old woman was admitted to our hospital (April 1988) with hypoglycaemia, weight loss of 20 kg and pain attacks in the upper abdomen. The reason for the hypoglycaemic attacks was a pancreatic tumour with already widespread liver metastases. The tumour proved to be active. Insulin levels (104 #E/ml; normal 1-20 gE/ml), C-peptide concentration (69 ng/ml; normal 0.6-5.4 ng/ml), serum glucose levels (150-250 rag/100 ml) and growth hor-925 mone levels (85.9 ng/ml; normal < 1 ng/ml) were elevated. In the same month the pancreatic tail with an islet cell carcinoma and the left liver lobe were resected, demonstrating widespread metastases in the liver. After 8 cycles of a 5-fluorouracil and streptozocin treatment, computed tomography scans demonstrated a small decrease in the size of the liver metastases. In March 1990 an ultrasound-guided liver biopsy, examined in the laboratory of Dr. Reubi demonstrated in more than 10% of all tumor cells highly positive somatostatin receptors. A Sandostatin treatment was started with 3 x 100 gg subcutaneously per day. In April 1990 an iodine 123 tyr-3-octretide scan was performed, which demonstrated only a faint, patchy, increased uptake in the liver (Fig. 2a) , which could only be interpreted as positive after knowledge of the sonographic and computed tomographic results. The scan revealed a significant pathological uptake in the right acetabulum (Fig. 2b) , which was suspected to be metastatic. X-radiographs demonstrated an osteolytic process in this region. The symptoms of hygolycaemia and the patient's general condition seriously worsened, and the patient started to complain of right-sided hip pain. In June 1990 a percutaneous radiation treatment of the right hip with 10 MV photons was started, up to a total dose of 36 Gy. A subsequent total hip replacement (Aug. 1990) only demonstrated osteonecrosis from the radiation therapy and no tumonr tissue. Despite continuing somatostatin treatment and a permanent glucose infusion, the patient died in Jan. 1991.
Discussion
Previous p a p e r s ( B l o o m a n d Polak 1980; Stefani et al. 1974) have already d e m o n s t r a t e d that, with the exception o f insulinomas, m o s t endocrine p a n c r e a t i c t u m o u r s are m a l i g n a n t a n d have metastasized at the time o f diagnosis. Case r e p o r t 1 describes one o f these rare, infiltrating, unresectable, endocrine-inactive islet cell t u m o u r s at the time o f diagnosis. (Junginger et al. 1990 ).
Because there is a wide variation in the clinical presentation o f endocrine p a n c r e a t i c t u m o u r s in m a n , there are t u m o u r s which present with signs and s y m p t o m s related to the h o r m o n a l hypersecretion f r o m these tum o u r s , others with s y m p t o m s related to the t u m o u r mass itself. In these latter cases, as d e m o n s t r a t e d in case r e p o r t 1, these often undifferentiated t u m o u r s do n o t Fig. 2a . The iodine 123 tyr-3-octreotide planar scan demonstrates significant pathological uptake in the right acetabulum, where xradiographs later demonstrated an osteolytic tumour (anterior view), b A 60-year-old woman with metastatic somatostatin receptor-positive pancreatic islet cell carcinoma. The iodine 123 tyr-3-octreotide single photon emission tomogram of the liver demonstrates a patchy, increased uptake in the metastases secrete considerable amounts of biologically active hormones, or the clinical picture is rather inconspicious (Lamberts et al. 1990b; Stefani et al. 1974) . Here the iodine 123 tyr-3-octreotide scan might be helpful in demonstrating somatostatin receptors on pancreatic tumours, which helps in the differential diagnosis of ductal adenocarcinomas, which have no somatostatin receptors from endocrine pancreatic carcinomas (Lamberts et al. 1990c) . Therefore, this method might be a safe alternative to in vivo octreotide application in the selection of insulinoma patients for chronic treatment with the drug, which has been previously proposed.
In the second patient, somatostatin receptors were shown earlier on the primary tumour. This was the indication for the somatostatin scan, because such specific receptors could be expected in the metastases also. For this reason, the known liver metastases could be detected as small areas of increased uptake in the liver, which were the reason for the increased insulin secretion in this patient. The scan demonstrated another more striking lesion in the right hip, which was found to be another metastasis from the insulinoma.
The benefit of the scan can be easily demonstrated in case report 2, as besides the already known liver metastases another large focus was detected in the right hip before clinical symptoms appeared, leading to surgical treatment. However, due to the liver metastases the hyperinsulinaemia persisted even under continuing octreotide medication.
In conclusion, we have confirmed in this study the results of iodine 123 tyr-3-octreotide scans from other groups (Lamberts et al. 1990a ). This method opens for the first time up the possibility of the localization of somatostatin receptor-positive tumours and their metastases. Second, this method offers a non-invasive procedure to determine tumour receptor status. Theoretically, this new approach of scintigraphic tumour detection might be extended to other receptor-containing tumours and by this way may offer an alternative to immunoscintigraphy with monoclonal antibodies.
